MyoKardia, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: San Francisco CA United States (2012)
Status: Acquired by Bristol-Myers Squibb (2020)

Organization Overview

First Clinical Trial
2014
NCT02329184
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

MyoKardia, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

mavacamten (Camzyos) (5 trials)

Drugs in Phase 2 Trials (2)

danicamtiv (1 trial)

myk-461 (5 trials)

Drugs in Phase 1 Trials (1)

myk-491 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 2)

Cardiomyopathy, Hypertrophic (Phase 3)

Heart Failure (Phase 1)

Hypertrophy (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 4